Marker Therapeutics, Inc.
About Marker Therapeutics, Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2021
- $0
- Net income
- -$12.2M
- Total assets
- $19.1M
- Market cap
- $23.7M
- Operating margin
- -363.5%
- Net margin
- -343.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $3.5M
- Operating expenses
- $16.4M
- Operating income
- -$12.9M
- Income tax
- -$15.2K
- Net income
- -$12.2M
- EPS (basic)
- $-0.79
- EPS (diluted)
- $-0.79
Balance sheet
- Total assets
- $19.1M
- Current assets
- $19.1M
- Total liabilities
- $2.3M
- Current liabilities
- $2.3M
- Shareholders’ equity
- $16.8M
Cash flow
- Operating cash flow
- -$12.0M
- Investing cash flow
- $2.1M
- Financing cash flow
- $9.9M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $23.7M
- EPS (diluted)
- $-0.79
- Shares outstanding
- 16.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 7, 1998
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $12.2M in FY2021.
- Revenue grew 186% from FY2021 to FY2025.
- Trading 35% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Marker Therapeutics, Inc..
Write a review
News about Marker Therapeutics, Inc.
News & sentiment via Polygon.io
